Tradestie Institutional Equity Comparison Engine

MLYS vs TYRA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TYRA Overall Edge

TYRA Captures Institutional Edge (2โ€“0 Pillars ยท 3โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Tyra Biosciences, Inc. Common Stock (TYRA) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, MLYS trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus TYRA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MLYS sits in BREAKDOWN (39th %ile IV; Dealer Gamma Walls on Pro) against TYRA sits in BREAKDOWN (3rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
MLYS N/M vs TYRA N/M Fwd P/E
Growth & Margin Winner TYRA
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner TYRA
1Y -66.6% vs +26.8% ยท 52W Pos 1% vs 20%
Options & Structure Winner Tie
BREAKDOWN (39th %ile IV) vs BREAKDOWN (3rd %ile IV)
MLYS NASDAQ
Mineralys Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$14.79
-3.52% 1D
Market Cap $1.4B
1M Return -27.14%
1Y Return -66.61%
Forward P/E N/M
Unified AI Score
58.9 / 100 HOLD
Tech 68.0 Fund 68.0 Flow 69.0 Mom 60.0
TYRA NASDAQ
Tyra Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$19.77
-1.27% 1D
Market Cap $1.3B
1M Return +6.75%
1Y Return +26.81%
Forward P/E N/M
Unified AI Score
32.4 / 100 SELL
Tech 25.0 Fund 46.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MLYS -66.61% TYRA +26.81% Spread: +93.42 pp (TYRA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MLYS TTM Op. Margin: 0.0% TYRA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLYS vs TYRA. Trailing 12-month operating profitability (MLYS 0.0% vs TYRA 0.0%) and valuation multiples (MLYS N/M vs TYRA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MLYS (2) vs TYRA (3)
Institutional Metric MLYS TYRA Criterion Row Winner
Market Capitalization Scale $1.4B $1.3B Larger Scale MLYS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -68.5% -34.9% Higher ROE TYRA
52-Week Range Position Momentum 1% ($15โ€“$47) 20% ($15โ€“$41) Stronger Trend TYRA
Beta / 30D Volatility Risk Regime 1.70ฮฒ ยท 89% Vol 0.79ฮฒ ยท 49% Vol Lower Realized Risk TYRA
Unified Institutional Score Composite Signal 58.9 / 100 (HOLD) 32.4 / 100 (SELL) Higher Composite MLYS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MLYS vs TYRA Buy Guide
MLYS BREAKDOWN
119d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 39th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MLYS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TYRA BREAKDOWN
76d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 3rd %ile
IV Regime Compressed (<25th %ile)
Live TYRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MLYS nor TYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.